AKAlexander S. Krylov

Alexander S. Krylov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander S. Krylov has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization of Response Dynamics Assessment for Targeted ¹⁷⁷Lu-PSMA Radioligand Therapy Using PET/CT, PSA, and SPECT/CT

    by A. V. Parnas, A. S. Krylov, A. V. Filimonov, V. V. Solomyany, V. S. Ilyakov, O. D. Baranova, A. A. Li, A. V. Klimov, А. В. Парнас, А. С. Крылов, et al.

    Purpose : To optimize the evaluation of response dynamics during PSMA-targeted radioligand therapy (RLT) ¹⁷⁷Lu-PSMA based on a comprehensive analysis of prostate-specific antigen (PSA), post-therapeutic single-photon emission computed tomography/ computed tomography (SPECT/CT), and positron emission tomography/computed tomography (PET/CT) with ¹⁸F-PSMA-1007 in patients with metastatic castration-resistant prostate cancer (mCRPC). Material and methods : A retrospective single-center study was conducted, including 78 patients with mCRPC who received 2 to 6 cycles of ¹⁷⁷Lu-PSMA-617 therapy. Monitoring included three levels: PSA dynamics (before each cycle), post-therapeutic SPECT/ CT (24 hours after each administration), and PET/CT with ¹⁸F-PSMA-1007 (baseline and after 2, 4, and 6 cycles). The dynamics of radiopharmaceutical uptake, SUV max values, and concordance between methods were assessed. The primary endpoint was progression-free survival (PFS) assessed by PET/CT. Results : The median PFS by PET/CT in the overall cohort was 9 months. Stratified by PET/CT dynamics after 2 cycles, median PFS was: positive dynamics — 14 months, divergent — 8 months, negative — 5 months (p30 % reduction in SUV max in bone lesions on SPECT/CT after the 1st cycle was associated with longer PFS (13.5 months vs. 5.5 months; p < 0.001). Concordance between PSA and PET/ CT was moderate (κ=0.44), with discordance observed in 17.9 % of cases. The highest concordance was between SPECT/CT and PET/ CT (κ=0.68-0.70). PSMA-negative progression was detected in 5 patients (6.4 %), with 4 of them showing decreasing or stable PSA levels. A >30 % reduction in SUV max in bone lesions on SPECT/CT after the 1st cycle was associated with longer PFS (13.5 months vs. 5.5 months; p < 0.001). No grade ≥3 adverse events were recorded. Conclusion : Combined monitoring (PSA + SPECT/CT after each cycle + PET/CT with ¹⁸F-PSMA-1007 every 2 cycles) is optimal for response assessment during ¹⁷⁷Lu-PSMA therapy. Isolated PSA assessment is insufficient due to high discordance with imaging methods. Post-therapeutic SPECT/CT allows outcome prediction, while PET/CT is essential for detecting PSMA-negative progression and making decisions on therapy continuation or cessation. The proposed three-level approach enables timely treatment individualization.

  • Open Access

    Therapy-induced neuroendocrine prostate cancer

    by M. P. Korchagin, K. A. Firsov, A. S. Krylov, V. B. Matveev

    Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a rare and aggressive form of the disease, driven by the tumor's adaptive response to standard androgen deprivation therapy (ADT). Although its primary detection rate is low, t-NEPC accounts for up to 30% of cases of progressive prostate cancer (PCa), according to large-scale international studies. However, despite a significant increase in publications in recent years, many aspects of t-NEPC diagnosis and treatment remain controversial and require validation through large-scale research. This article presents a clinical case of t-NEPC and reviews current data on the molecular-genetic mechanisms and key signaling pathways underlying neuroendocrine differentiation. The aim of this publication is to expand the evidence base and improve the understanding of the clinical manifestations, diagnostic challenges, and therapeutic strategies for this rare disease.

  • Open Access

    Sequential therapy with radium-223 chloride and 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer

    by E. A. Nikolaeva, M. M. Sinelnikov, A. S. Krylov, A. D. Ryzhkov, B. I. Dolgushin

    Objective : to evaluate the efficacy and safety of sequential treatment with radium-223 chloride (Ra-223) followed by 177 Lu-PSMA in patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice. Material and Methods. This retrospective single-center study included 16 mCRPC patients who received at least 4 Ra-223 injections followed by 177 Lu-PSMA therapy (at least 2 cycles) between 2022 and 2026. The median age was 69.5 years. All patients had bone metastases; 94 % had prior docetaxel treatment. We assessed biochemical response (prostate-specific antigen (PSA) decline >50 %), radiological response using PSMA PET/CT and bone scintigraphy, and toxicity according to CTCAE v5.0. Results. Twelve patients received a full course of Ra-223 (6 injections). Biochemical response to Ra-223 was observed in 2 (12.5 %) patients, radiological response in 5 (31.3 %). After a median interval of 2.2 months, 177 Lu-PSMA therapy was initiated (median 5 cycles). Biochemical response to 177 Lu-PSMA was achieved in 11 (68.8 %) patients, including 7 out of 9 who had progressed on Ra-223. Radiological response was recorded in 9 (56.3 %) patients. Median PSA level decreased from 130.5 to 15.9 ng/mL. Severe (grade 3) hematological toxicity occurred in 2 (12.5 %) patients, xerostomia in 3 (18.8 %). Conclusion. Sequential therapy with Ra-223 and 177 Lu-PSMA demonstrates high efficacy (68.8 % biochemical response rate) and an acceptable safety profile in mCRPC patients, including those with progression on Ra-223, supporting the feasibility of this therapeutic strategy in clinical practice.

  • Van Neck-Odelberg Syndrome. Case Series

    by S. N. Prokhorov, N. V. Kochergina, A. D. Ryzhkov, A. S. Krylov, A. B. Bludov, E. A. Nickolaeva

    Purpose : To demonstrate radiological manifestations of a rare benign disease of childhood. Materials and Methods: The study included 7 cancer patients examined to rule out bone metastases. The sample was collected in 2024 and 2025. All patients underwent bone scans, supplemented by SPECT/CT. Results : In all cases, classic manifestations of the condition described in the literature were observed. Conclusion : Primarily due to its rarity, the syndrome can be challenging to differentiate from other conditions, including malignancies. Raising awareness will help avoid unnecessary treatment and diagnostic interventions.

  • Intrathecal chemotherapy in the complex treatment of children with parameningeal rhabdomyosarcoma with intracranial spread and/ or leptomeningeal metastasis

    by A. D. Rodina, V. G. Polyakov, A. S. Krylov, A. L. Kashanina, T. V. Gorbunova, S. R. Varfolomeeva

    Introduction . Parameningeal rhabdomyosarcoma with intracranial spread is a highly aggressive pediatric malignancy with a high risk of leptomeningeal metastasis. Historically, central nervous system (CNS) involvement was considered an incurable condition with a survival rate of no more than 10–20 %. The bloodbrain barrier is the primary barrier to the penetration of most drugs and the creation of effective concentrations. Therefore, the search for effective and non-toxic methods for controlling leptomeningeal metastases is one of the most pressing challenges in pediatric oncology. Intrathecal chemotherapy (ITCT) delivers cancer drugs directly into the cerebrospinal fuid, bypassing the BBB. It enables high concentrations of medication to directly target cells, reducing systemic toxicity. The purpose of the study was to evaluate the effcacy and safety of intrathecal chemotherapy in a multidisciplinary approach to the treatment of children with parameningeal rhabdomyosarcoma with intracranial spread and/or leptomeningeal metastasis, and to improve survival rates in this cohort of children. Material and Methods . The study included 21 patients with a histologically verifed diagnosis of parameningeal rhabdomyosarcoma with intracranial spread and/or leptomeningeal metastasis, who received treatment at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology of the Russian Academy of Medical Sciences from 2021 to 2024. The study was approved by the local ethics committee. Results . With a 34.3-month median follow-up, the overall 2-year survival rate was 65 %. This indicates the effectiveness of early tumor control by overcoming the blood-brain barrier. The overall 2-year survival rate was signifcantly higher in both the prophylactic and therapeutic frst-line intrathecal chemotherapy groups than in the relapse group (80 % vs 20 %, pConclusion . Intensive intrathecal chemotherapy in the combination treatment of children with parameningeal rhabdomyosarcoma with intracranial extension and/or leptomeningeal metastasis is an effective and safe method for treating and preventing CNS tumor cell infltration. This therapy can signifcantly improve survival of patients with extremely unfavorable prognosis.

  • Standardized Method for Quantitative Assessment of the Efficacy of Bone-Targeted Radionuclide Therapy with Radium-223 Chloride in Patients with Prostate Cancer.

    by E. A. Nikolaeva, A. S. Krylov, A. A. Ryzhkov, S. N. Prokhorov

    Introduction : Radium-223 (²²³Ra) therapy improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC), but response monitoring is challenging due to the lack of classic PSA response. Standardized assessment methods based on imaging are needed. Objective : To develop and evaluate a comprehensive diagnostic algorithm for quantitative monitoring of the efficacy of ²²³Ra therapy based on SPECT/CT and bone scintigraphy data. Materials and Methods : A prospective single-center study included 114 mCRPC patients who received 2 to 6 injections of ²²³Ra. All patients underwent planar bone scintigraphy with automated Bone Scan Index (aBSI) calculation, quantitative SPECT/CT with standardized uptake value (SUV max , SUV mean ) and percent injected dose (%ID) calculation, PSMA-ligand PET/CT, assessment of biochemical markers (PSA, LDH, ALP) and clinical status. Results : In patients who completed the full course (6 injections, n = 64), a statistically significant decrease in all quantitative parameters was revealed: SUV max (from 51.9 ± 16.4 to 30.5 ± 11.2; p < 0.001), SUV mean (from 2.87 ± 0.63 to 2.43 ± 0.58; p = 0.021), %ID (from 12.4 ± 3.1 to 10.8 ± 2.6; p = 0.037), aBSI (from 2.15 ± 0.38 to 1.70 ± 0.31; p = 0.005), as well as levels of PSA, LDH and ALP. Imaging parameters significantly correlated with ALP levels, pain syndrome, functional status, and the development of hematological toxicity. High baseline SUV mean , %ID, and aBSI values were associated with an increased risk of myelosuppression. Conclusion : Quantitative SPECT/CT parameters (SUV max , SUV mean , %ID) and scintigraphy parameters (aBSI) are objective markers of the efficacy of ²²³Ra therapy, reflecting the dynamics of the metabolic activity of bone metastases and allowing to predict the development of hematological toxicity. A comprehensive multiparameter approach improves the accuracy of treatment response assessment.

  • Open Access

    177Lu-PSMA therapy in patients with prostate cancer. “Holiday” strategy. Pilot study

    by Aleksandr V. Parnas, A. S. Krylov, B. M. Khakulova, A. V. Filimonov, A. I. Pronin, V. S. Ilyakov, A. A. Rumyantsev

    Aim. To evaluate the strategy of temporary interruption of prostate-specific membrane antigen (PSMA)-targeted therapy 177Lu-PSMA. Materials and methods. A retrospective observational study was conducted which included 30 patients divided into two groups: treatment group (n = 16) received 2 to 4 fractions of 177Lu-PSMA and switched to observation (“holiday”), and control group (n = 14) completed the standard 6 fractions. Prostate-specific antigen (PSA) reduction rates, progression-free survival (PFS), adverse event rate, and effect of combination therapy (177Lu-PSMA + enzalutamide) were evaluated. Results. In the first group, a decrease in PSA by more than 50 % was observed in 100 % of patients, in the second group in 92.3 %. The median PFS was 8 months in the first group and 6 months in the second. No serious adverse events ( grade II) were observed. Combination with enzalutamide was associated with improved PFS (median 12 months vs 6 months). Patients with poorly differentiated tumors (Gleason ≥9) and previous 223Ra therapy had worse prognosis (median PFS 5 months). Conclusion. Interruption of 177Lu-PSMA therapy after 2–4 fractions with subsequent continuation in case of progression is a promising strategy that allows balancing between efficacy and safety. This approach is especially relevant for patients with limited metastatic burden and high risk of hematological toxicity. However, given the limited and heterogeneous patient sample, a detailed study in a larger patient cohort is necessary.

  • Open Access

    Radioligand therapy with 177Lu-PSMA in castration-resistant prostate cancer: a literature review and case series

    by Maria I. Volkova, Alexander S. Krylov, Dmitry A. Nosov, Boris Ya. Alekseev

    Overexpression and ligand-dependent internalization of prostate-specific membrane antigen (PSMA), followed by its accumulation in prostate cancer (PCa) cells, make this glycoprotein a good target for radionuclide-based targeted therapy. Currently, the only drug in this group with efficacy proven in a large randomized clinical study in patients with metastatic castration-resistant PCa is 177Lu-PSMA-617. The article presents an overview of the data on the mechanism of action and the results of completed studies of radioligand therapy (RLT) with 177Lu-PSMA for PCa, the current indications for this type of treatment in patients with a castration-resistant phase of the disease, and practical guidelines for RLT, including its planning, implementation, monitoring of effectiveness, and radiation protection measures. Clinical cases of patients with partial response/stabilization of the disease during RLT, significant improvement/complete response, and progression of PCa are presented.

  • Open Access

    Interim Results of a Phase I/II Clinical Study to Assess the Safety And Efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-TATE Produced by the N.N. Blokhin National Medical Research Center of Oncology in Patients with Neuroendocrine Neoplasia

    by O. D. Baranova, A. S. Krylov, Yа. A. Zhulikov, E. V. Artamonova, A. A. Markovich, D. V. Likhosherstova, A. V. Filimonov, P. E. Tulin, B. I. Dolgushin, I. S. Stilidi

    Introduction : Peptide-receptor radionuclide therapy (PRRT) is currently a well-studied treatment option for patients with neuroendocrine tumors. Based on the results of the Phase III NETTER-1 and NETTER-2 trials, 177 Lu-DOTA-TATE therapy has become the standard for second- and subsequent-line therapy. However, there are currently no domestic studies investigating PRRT. In our study, we evaluated the efficacy and safety of 177 Lu-DOTA-TATE, a radiopharmaceutical drug synthesized in the cyclotron-radiochemistry laboratory of the Department of Radionuclide Diagnostics and Therapy at the N.N. Blokhin National Medical Research Center of Oncology and having undergone preclinical trials, in patients with neuroendocrine neoplasias (NENs). Materials and Methods : This phase I/II study enrolled patients with metastatic NENs of various locations with Ki-67 177 Lu-DOTA-TATE radiopharmaceutical every 8–10 weeks, along with extended-release somatostatin analogs. The primary endpoints were response rate (disease control) of ≥​​ 6 months and safety. Secondary endpoints were objective response rate, progression-free survival (PFS), and overall survival (OS). Patients were enrolled from June 2024 to July 2025. This study analyzes the Įrst 11 patients enrolled in the study. Results : Eleven patients were included in this analysis. The median age was 54 years. Primary tumor localizations: gastroenteropan‑ creatic (GEP) NEN — 6 patients (54.5 %), pheochromocytomas/paragangliomas — 3 patients (27.3 %), lung NEN and NEN metastases from the esophagus — 1 patient each (9.3 %). Median Ki-67 was 10 % (5–25 %). All patients had previously received everolimus therapy, 9 patients (81.8 %) — chemotherapy. The objective response rate (ORR) was 54.5 %, all responses were partial. Disease stabilization (DS) was recorded in 36.4 %. Disease control (DC) ≥​​ 6 months was noted in 90.9 % of cases. Median PFS and OS with a median follow-up of 11.3 months were not achieved. Grade 3–4 leukopenia was recorded in 2 patients (18.2 %). No decrease in renal function was noted. One serious adverse event associated with disease progression was recorded: pleurisy, requiring thoracentesis for fluid evacuation. Conclusion : Peptide-receptor radionuclide therapy with 177 Lu-DOTA-TATE, manufactured at the Blokhin National Medical Research Center of Oncology, resulted in high ORR and CFS rates in patients with NEN of various locations. Clinically signiĮcant myelosuppres‑ sion was observed in 18.2 % of cases.